Last ¥1,768 JPY
Change Today +21.00 / 1.20%
Volume 3.3M
4568 On Other Exchanges
Symbol
Exchange
Tokyo
OTC US
OTC US
Frankfurt
As of 1:00 AM 11/26/14 All times are local (Market data is delayed by at least 15 minutes).

daiichi sankyo co ltd (4568) Snapshot

Open
¥1,753
Previous Close
¥1,747
Day High
¥1,772
Day Low
¥1,748
52 Week High
01/10/14 - ¥2,007
52 Week Low
10/17/14 - ¥1,570
Market Cap
1.3T
Average Volume 10 Days
3.3M
EPS TTM
--
Shares Outstanding
709.0M
EX-Date
03/27/15
P/E TM
--
Dividend
¥60.00
Dividend Yield
3.39%
Current Stock Chart for DAIICHI SANKYO CO LTD (4568)

Related News

No related news articles were found.

daiichi sankyo co ltd (4568) Related Businessweek News

No Related Businessweek News Found

daiichi sankyo co ltd (4568) Details

Daiichi Sankyo Company, Limited engages in the research, development, manufacture, import, sale, and marketing of pharmaceutical products in Japan and internationally. The company’s product portfolio includes generic pharmaceuticals, vaccines, and over-the-counter (OTC) medicines. Its principal products include Olmesartan, an anti-hypertensive agent; Prasugrel, an antiplatelet agent; Edoxaban, an anticoagulant; Memary and Donepezil for the treatment of alzheimer’s disease; Nexium for treating reflux esophagitis; Pralia for osteoporosis; Tenelia for treatment for type 2 diabetes mellitus; and ActHIB, a haemophilus b conjugate vaccine, as well as Denosumab to treat and prevent various bone disorders, including osteoporosis and bone metastases. The company’s products OTC comprise Loxonin S, an analgesic and anti-inflammatory drug; Transino II, a drug for the improvement of spots; and Traful Ointment for stomatitis treatment. It also markets therapies in hypertension, dyslipidemia, and bacterial infections, as well as treatments for thrombotic disorders. In addition, the company researches and develops therapies in oncology and cardiovascular-metabolic diseases, including biologics. Further, it manufactures and sells cosmetics, medical equipment, food products, drinking water, active pharmaceutical ingredients, and intermediates, as well as pharmaceuticals and drugs for animals. Daiichi Sankyo Company, Limited was founded in 1899 and is headquartered in Tokyo, Japan.

32,791 Employees
Last Reported Date: 06/23/14
Founded in 1899

daiichi sankyo co ltd (4568) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

daiichi sankyo co ltd (4568) Key Developments

Daiichi Sankyo Company Announces Dividend for the Second Quarter Ended Sep. 30, 2014, Payable on December 1, 2014; Provides Dividend Guidance for the Fiscal Year Ending March 31, 2015

Daiichi Sankyo Company, Limited announced an interim dividend of ¥30 per share for the second quarter ended Sep. 30, 2014. The Dividend is payable on December 1, 2014. The company provided interim dividend guidance for the fiscal year ending March 31, 2015. The company expects, to pay a year end dividend of JPY 30.00 per share compared to a dividend of JPY 30.00 per share announced for same period of previous year.

Daiichi Sankyo Company, Limited Announces Consolidated and Company Earnings Results for the Six Months Ended September 30, 2014; Revises Earnings Guidance for the Year Ending March 31, 2015

Daiichi Sankyo Company, Limited announced consolidated and company earnings results for the six months ended September 30, 2014. For the period, on consolidated basis, the company reported revenue of JPY 525,405 million against JPY 516,764 million a year ago. Operating profit was JPY 68,811 million against JPY 52,681 million a year ago. Profit before tax was JPY 65,367 million against JPY 43,861 million a year ago. Profit for the period was JPY 50,308 million against JPY 31,609 million a year ago. Profit attributable to owners of the company was JPY 50,326 million or JPY 71.34 diluted earnings per share against JPY 33,479 million or JPY 47.47 diluted earnings per share a year ago. Net cash flows from operating activities were JPY 56,753 million against cash used from operating activities JPY 24,891 million a year ago. Acquisitions of property, plant and equipment was JPY 20,045 million against JPY 22,095 million a year ago. Acquisition of intangible assets was JPY 21,395 million against JPY 3,109 million a year ago. For the period, on company basis, the company reported revenue of JPY 429,590 million against JPY 429,133 million a year ago. Operating profit was JPY 58,738 million against JPY 50,112 million a year ago. Profit before tax was JPY 60,663 million against JPY 50,198 million a year ago. Profit attributable to owners of the company was JPY 35,496 million against JPY 35,210 million a year ago. The company revised earnings guidance for the full year of ending March 31, 2015. For the full year, the company expects revenue of JPY 900,000 million against as previously forecasted of JPY 920,000 million. Operating profit is expected to be JPY 100,000 million against as previously forecasted to be JPY 120,000 million. Profit before tax is expected to be JPY 100,000 million against as previously forecasted to be JPY 120,000 million. Profit attributable to owners of the company is expected to be JPY 65,000 million or JPY 92.33 basic earnings per share against as previously forecasted to be JPY 78,000 million or JPY 110.80 basic earnings per share.

Daiichi Sankyo Company, Limited, Q2 2015 Earnings Call, Nov 04, 2014

Daiichi Sankyo Company, Limited, Q2 2015 Earnings Call, Nov 04, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4568:JP ¥1,767.50 JPY +21.00

4568 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Array BioPharma Inc $3.95 USD +0.025
BioCryst Pharmaceuticals Inc $11.20 USD +0.04
BioMerieux €85.30 EUR -0.90
Infinity Pharmaceuticals Inc $15.26 USD +0.55
Ipsen SA €41.85 EUR -0.275
View Industry Companies
 

Industry Analysis

4568

Industry Average

Valuation 4568 Industry Range
Price/Earnings 14.6x
Price/Sales 1.0x
Price/Book 1.1x
Price/Cash Flow 14.8x
TEV/Sales 0.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DAIICHI SANKYO CO LTD, please visit www.daiichisankyo.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.